CRISPR Therapeutics AG (CRSP) Equity Ratio (2015 - 2026)

CRISPR Therapeutics AG has disclosed Equity Ratio across 12 years of filings, most recently posting 0.67 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.67, down 21.17% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.67 (down 21.17% YoY), and the FY2025 annual result was 0.85, down 1.55% from the prior year.
• Equity Ratio came in at 0.67 for Q1 2026 at CRISPR Therapeutics AG, down from 0.85 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.86 in Q4 2024 to a low of 0.67 in Q1 2026.
• The 5-year median for Equity Ratio is 0.84 (2023), against an average of 0.83.
• Across the five-year window, Equity Ratio increased 3.84% in 2024 and fell 21.17% in 2026, its largest moves.
• CRISPR Therapeutics AG's Equity Ratio stood at 0.84 in 2022, then rose by 1.0% to 0.84 in 2023, then climbed by 2.05% to 0.86 in 2024, then retreated by 1.55% to 0.85 in 2025, then dropped by 21.53% to 0.67 in 2026.
• The last three Equity Ratio figures came in at 0.67 (Q1 2026), 0.85 (Q4 2025), and 0.85 (Q3 2025), per Business Quant data.